Renin-angiotensin system blockers may create more risk than reward for sodium-depleted cardiovascular patients with high plasma renin levels

American Journal of Hypertension

Volumn 26, Issue 6, 2013, Pages 727-738

  Sealey, Jean E ^a   Alderman, Michael H ^b   Furberg, Curt D ^c   Laragh, John H ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

angiotensin receptor blocker; angiotensin converting enzyme inhibitor; blood pressure; cardiovascular mortality; diuretics; hypertension; hypotension; plasma renin; PRA; sodium depletion.

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NATRIURETIC FACTOR; RENIN; RENIN INHIBITOR; SPIRONOLACTONE; URIC ACID;

ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG USE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM DEPLETION; SYSTEMATIC REVIEW; UREA NITROGEN BLOOD LEVEL;

ANGIOTENSIN RECEPTOR BLOCKER; ANGIOTENSIN-CONVERTING ENZYME INHIBITOR; BLOOD PRESSURE; CARDIOVASCULAR MORTALITY; DIURETICS; HYPERTENSION; HYPOTENSION; PLASMA RENIN; PRA; SODIUM DEPLETION.;

CARDIOVASCULAR DISEASES; HUMANS; RENIN; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SODIUM; SURVIVAL RATE; WORLD HEALTH;

EID: 84877726974     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpt034     Document Type: Article

References (40)

1. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, Buhler FR. Essential hypertension: Renin and aldosterone, heart attack and stroke. N Engl J Med 1972; 286:441-449.
2. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324:1098-1104.
3. Gonzalez MC, Cohen HW, Sealey JE, Laragh JH, Alderman MH. Enduring direct association of baseline plasma renin activity with all-cause and cardiovascular mortality in hypertensive patients. Am J Hypertens 2011; 24:1181-1186.
4. CONSENSUS. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987; 316:1429-1435.
5. SOLVD. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
6. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins M. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival And Ventricular Enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327:669-677.
7. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Pogue J, Moye L, Braunwald E. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. ACEInhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355:1575-1581.
8. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:1893-1906.
9. Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, Cherif Papst C, Smith DA, Dahlof B. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009; 119:530-537.
10. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
11. RALES. Effectiveness of spironolactone added to an angiotensinconverting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996; 78:902-907.
12. Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005; 46:42-531.
13. Laragh JH, Sealey JE. The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure. Am J Hypertens 2011; 24:1164-1180.
14. Masson S, Solomon S, Angelici MS, Latini R, Anand IS, Prescott M, Maggioni AP, Tognoni G, Cohn JN. Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: Data from the Valsartan Heart Failure Trial (Val-HeFT). J Card Fail 2010; 16:964-970.
15. Muhlestein JB, May HT, Bair TL, Prescott MF, Horne BD, White R, Anderson JL. Relation of elevated plasma renin activity at baseline to cardiac events in patients with angiographically proven coronary artery disease. Am J Cardiol 2010; 106:764-769.
16. Tomaschitz A, Pilz S,Ritz E, Morganti A, Grammer T, Amrein K, Boehm BO, Marz W. Associations of plasma renin with 10-year cardiovascular mortality, sudden cardiac death, and death due to heart failure. Eur Heart J. 2011; 32:2642-2649.
17. Verma S, Gupta M, Holmes DT, Xu L, Teoh H, Gupta S, Yusuf S, Lonn EM. Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. Eur Heart J 2011; 32:2135-2142.
18. Hall JE, Guyton AC, Brands MW. Control of sodium excretion and arterial pressure by intrarenal mechanisms and the renin-angiotensin system. In Laragh JH, Brenner BM (eds), Hypertension: Pathophysiology, Diagnosis, and Management. 2nd edn. Raven Press; New York, 1995, p.p. 1451-1475
19. Hall JE. Guyton and Hall Textbook of Medical Physiology. 12th ed. Elsevier Saunders: Philadelphia, 2011.
20. Hall JE, Guyton AC, Smith MJ Jr, Coleman TG. Blood pressure and renal function during chronic changes in sodium intake: Role of angiotensin. Am J Physiol 1980; 239:F271-F280.
21. Laragh JH. The role of aldosterone in man. Evidence for regulation of electrolyte balance and arterial pressure by a renal-adrenal system which may be involved in malignant hypertension. JAMA 1960; 174:293-295.
22. Sealey JE, Laragh JH. A proposed cybernetic system for sodium and potassium homeostasis: Coordination of aldosterone and intrarenal physical factors. Kidney Int 1974; 6:281-290.
23. Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH. Efficacy and safety of dual blockade of the renin-angiotensin system: Meta-analysis of randomised trials. BMJ. 2013; 346:f360. Published 02 March 2013.
24. Susantitaphong P, Sewaralthahab K, Balk EM, Eiam-Ong S, Madias NE, Jaber BL. Efficacy and safety of combined vs. single renin-angiotensinaldosterone system blockade in chronic kidney disease: A meta-analysis. Am J Hypertens. 2013; 26:424-441.
25. Sealey JE, James GD, Laragh JH. Interpretation and guidelines for the use of plasma and urine aldosterone and plasma angiotensin II, angiotensinogen, prorenin, peripheral, and renal vein renin tests. In Laragh JH, Brenner BM (ed), Hypertension: Pathophysiology, Diagnosis, and Management. 2nd edd. Raven Press: New York, 1995, pp. 1953-1968.
26. Sim JJ, Bhandari SK, Shi J, Kalantar-Zadeh K, Rasgon SA, Sealey JE, Laragh JH. Plasma renin activity (PRA) levels and antihypertensive drug use in a large healthcare system. Am J Hypertens 2012; 25:379-388.
27. Laragh JH. Laragh's Lessons in Renin System Pathophysiology for Treating Hypertension and Its Fatal Cardiovascular Consequences. Elsevier Science: New York, 2002.
28. Sealey JE. Plasma renin activity and plasma prorenin assays. Clin Chem 1991; 37:1811-1819.
29. Sealey JE, Parra D, Rosenstein R, Laragh JH. 'Effective' plasma renin activity: A derived measure for assessing residual plasma renin activity in patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Hypertension 2010; 55:e16; author reply e7.
30. Bonfils PK, Damgaard M, Taskiran M, Goetze JP, Norsk P, Gadsboll. Impact of diuretic treatment and sodium intake on plasma volume in patients with compensated systolic heart failure. Eur J Heart Fail 2010;12:995-1001.
31. Geyskes GG, Boer P, Vos J, Leenen FH, Mees EJ. Effect of salt depletion and propranolol on blood pressure and plasma renin activity in various forms of hypertension. Circ Res 1975; 36:248-256.
32. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990;82:1730-1736.
33. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsarinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372:547-553.
34. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Xiang Z, Brunel P, Pfeffer MA. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367:2204-2213.
35. Elsner D. Changes in neurohumoral systems during the development of congestive heart failure: Impact on cardiovascular and renal function. Eur Heart J. 1995; 16:52-58.
36. Cody RJ, Covit AB, Schaer GL, Laragh JH, Sealey JE, Feldschuh J. Sodium and water balance in chronic congestive heart failure. J Clin Invest. 1986; 77:1441-1452.
37. Paterna S, Parrinello G, Cannizzaro S, Fasullo S, Torres D, Sarullo FM, Di Pasquale P. Medium term effects of different dosage of diuretic, sodium, and fluid administration on neurohormonal and clinical outcome in patients with recently compensated heart failure. Am J Cardiol 2009; 103:93-102.
38. Alderman MH, Cohen HW. Dietary sodium intake and cardiovascular mortality: Controversy resolved? Am J Hypertens 2012; 25:727-734.
39. Dinicolantonio JJ, Pasquale PD, Taylor RS, Hackam DG. Low sodium versus normal sodium diets in systolic heart failure: Systematic review and meta-analysis. Heart, published online 24 January 2013 (doi:10.1136/heartjnl- 2012-302337).
40. Sealey JE, Laragh JH. Aliskiren, the first renin inhibitor for treating hypertension: Reactive renin secretion may limit its effectiveness. Am J Hypertens 2007; 20:587-597.